Company: INDP
Filing Date: 2025-03-27
Form Type: DRS
Source: 0001641172-25-000975
Chunk: 2

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-27
Form: DRS
Chunk 2
---
US

<div align='center'>Indaptus Therapeutics, Inc.

Up to Shares of Common Stock and accompanying

Common Warrants to Purchase up to Shares of Common Stock

Up to Pre-funded Warrants to Purchase up to Shares of Common Stock

and accompanying Common Warrants to Purchase up to Shares of Common Stock

Up to Placement Agent Warrants to Purchase up to Shares of Common Stock

Up to Shares of Common Stock Issuable Upon Exercise of the Common Warrants,

Pre-funded Warrants and Placement Agent Warrants</div>

We are offering in a best-efforts offering up to shares of common stock, par value $0.01 per share of Indaptus Therapeutics, Inc., a Delaware Company (“Indaptus”, the “Company”, “our company”, “we” or “us”), together with up to common warrants to purchase up to shares of common stock at an assumed combined public offering price of $ per share and common warrant pursuant to this prospectus, which was the closing price of our shares of common stock on the Nasdaq Capital Market (“Nasdaq”) on , 2025. The shares of common stock and common warrants will be sold in a fixed combination, with each share accompanied by one warrant to purchase one share.

We are also offering to those purchasers, if any, whose purchase of our shares of common stock in this offering would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common stock immediately following the consummation of this offering, the opportunity, in lieu of purchasing shares of common stock, to purchase pre-funded warrants to purchase shares of common stock. Each pre-funded warrant will be immediately exercisable for one share at any time at the option of the holder until such pre-funded warrant is exercised in full, provided that the holder will be prohibited from exercising pre-funded warrants for shares of common stock if, as a result of such exercise, the holder, together with its affiliates and certain related parties, would own more than 4.99% (or, at the election of the purchaser, 9.99%) of the total number of shares of common stock then issued and outstanding. The assumed combined purchase price of each pre-funded warrant and common warrant is $ (which is equal to the assumed combined public offering price per share and common warrant to be sold in this offering minus $0.01, the exercise price per